Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 14.88
HSKA's Cash-to-Debt is ranked higher than
63% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. HSKA: 14.88 )
Ranked among companies with meaningful Cash-to-Debt only.
HSKA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.27  Med: 0.84 Max: No Debt
Current: 14.88
Equity-to-Asset 0.69
HSKA's Equity-to-Asset is ranked higher than
64% of the 216 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. HSKA: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
HSKA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.59 Max: 0.78
Current: 0.69
0.02
0.78
Interest Coverage 118.84
HSKA's Interest Coverage is ranked higher than
54% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. HSKA: 118.84 )
Ranked among companies with meaningful Interest Coverage only.
HSKA' s Interest Coverage Range Over the Past 10 Years
Min: 1.89  Med: 16.29 Max: 118.84
Current: 118.84
1.89
118.84
Piotroski F-Score: 5
Altman Z-Score: 9.77
Beneish M-Score: -2.37
WACC vs ROIC
5.29%
18.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 13.01
HSKA's Operating Margin % is ranked higher than
75% of the 221 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. HSKA: 13.01 )
Ranked among companies with meaningful Operating Margin % only.
HSKA' s Operating Margin % Range Over the Past 10 Years
Min: -1.83  Med: 3.94 Max: 13.01
Current: 13.01
-1.83
13.01
Net Margin % 10.45
HSKA's Net Margin % is ranked higher than
81% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. HSKA: 10.45 )
Ranked among companies with meaningful Net Margin % only.
HSKA' s Net Margin % Range Over the Past 10 Years
Min: -1.53  Med: 2.93 Max: 42.28
Current: 10.45
-1.53
42.28
ROE % 17.38
HSKA's ROE % is ranked higher than
82% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. HSKA: 17.38 )
Ranked among companies with meaningful ROE % only.
HSKA' s ROE % Range Over the Past 10 Years
Min: -2.49  Med: 4.84 Max: 140.27
Current: 17.38
-2.49
140.27
ROA % 11.26
HSKA's ROA % is ranked higher than
87% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. HSKA: 11.26 )
Ranked among companies with meaningful ROA % only.
HSKA' s ROA % Range Over the Past 10 Years
Min: -1.49  Med: 3.03 Max: 61.02
Current: 11.26
-1.49
61.02
ROC (Joel Greenblatt) % 50.10
HSKA's ROC (Joel Greenblatt) % is ranked higher than
81% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.64 vs. HSKA: 50.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HSKA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5.69  Med: 15.53 Max: 53.51
Current: 50.1
-5.69
53.51
3-Year Revenue Growth Rate 9.10
HSKA's 3-Year Revenue Growth Rate is ranked higher than
62% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. HSKA: 9.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HSKA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.9  Med: 1.85 Max: 10.4
Current: 9.1
-16.9
10.4
3-Year EBITDA Growth Rate 141.70
HSKA's 3-Year EBITDA Growth Rate is ranked higher than
99% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. HSKA: 141.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HSKA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: -18.4 Max: 141.7
Current: 141.7
-63.9
141.7
GuruFocus has detected 1 Warning Sign with Heska Corp $HSKA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HSKA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541940    SIC: 742
Compare:NAS:VIVO, NAS:NEO, NAS:NRCIB, NYSE:ARA, NAS:LNTH, NAS:NTRA, NAS:BEAT, NYSE:ENZ, NAS:ALOG, NAS:QDEL, NYSE:NVTA, NAS:RDNT, NAS:NVDQ, NAS:OXFD, NAS:KANG, NAS:SRDX, NAS:PACB, NAS:QTNT, NAS:ONVO, NAS:GHDX » details
Traded in other countries:HSKN.Germany,
Headquarter Location:USA
Heska Corp is engaged in developing, manufacturing, marketing, selling and supporting veterinary products. The Company's core focus is on the canine and feline companion animal health markets.

Heska Corp was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. The Company develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it provides high value products. The Company's business is comprised of two reportable segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment includes mainly for canine and feline use, blood testing instruments and supplies as well as single use products and services such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. These products are sold directly to veterinarians by the Company as well as through distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals. All OVP products are sold by third parties under third party labels. It provides line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases and Electrolytes; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is a blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The Element POC Blood Gas & Electrolyte Analyzer is a handheld, wireless analyzer which delivers rapid blood gas, electrolyte, metabolite, and basic blood chemistry testing. EPOC features test cards with room temperature storage which can provide results with less than 100 uL of sample as well as WiFi and Bluetooth connectivity. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories in Loveland, Colorado and Fribourg, Switzerland which both provide blood testing using its ALLERCEPT Definitive Allergen Panels. Its competitors include: IDEXX Laboratories, Inc., Abaxis, Inc. and Synbiotics Corporation. The Company may be or subject to extensive regulation by governmental authorities in the United States, including the USDA and the FDA, and by similar agencies in other countries.

Ratios

vs
industry
vs
history
PE Ratio 52.77
HSKA's PE Ratio is ranked lower than
70% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.35 vs. HSKA: 52.77 )
Ranked among companies with meaningful PE Ratio only.
HSKA' s PE Ratio Range Over the Past 10 Years
Min: 0.49  Med: 34.84 Max: 604
Current: 52.77
0.49
604
Forward PE Ratio 52.36
HSKA's Forward PE Ratio is ranked lower than
87% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.63 vs. HSKA: 52.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 52.77
HSKA's PE Ratio without NRI is ranked lower than
70% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.61 vs. HSKA: 52.77 )
Ranked among companies with meaningful PE Ratio without NRI only.
HSKA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.49  Med: 34.85 Max: 604
Current: 52.77
0.49
604
Price-to-Owner-Earnings 229.40
HSKA's Price-to-Owner-Earnings is ranked lower than
94% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.37 vs. HSKA: 229.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HSKA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.83  Med: 30.77 Max: 8397
Current: 229.4
2.83
8397
PB Ratio 7.52
HSKA's PB Ratio is ranked lower than
78% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. HSKA: 7.52 )
Ranked among companies with meaningful PB Ratio only.
HSKA' s PB Ratio Range Over the Past 10 Years
Min: 0.22  Med: 1.27 Max: 19.66
Current: 7.52
0.22
19.66
PS Ratio 5.52
HSKA's PS Ratio is ranked lower than
62% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. HSKA: 5.52 )
Ranked among companies with meaningful PS Ratio only.
HSKA' s PS Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.78 Max: 6.06
Current: 5.52
0.12
6.06
Price-to-Free-Cash-Flow 136.59
HSKA's Price-to-Free-Cash-Flow is ranked lower than
90% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.66 vs. HSKA: 136.59 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HSKA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.44  Med: 20.16 Max: 590.34
Current: 136.59
2.44
590.34
Price-to-Operating-Cash-Flow 83.99
HSKA's Price-to-Operating-Cash-Flow is ranked lower than
95% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.27 vs. HSKA: 83.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HSKA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.36  Med: 26.29 Max: 280.59
Current: 83.99
2.36
280.59
EV-to-EBIT 39.64
HSKA's EV-to-EBIT is ranked lower than
68% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.02 vs. HSKA: 39.64 )
Ranked among companies with meaningful EV-to-EBIT only.
HSKA' s EV-to-EBIT Range Over the Past 10 Years
Min: -111.6  Med: 22.3 Max: 172
Current: 39.64
-111.6
172
EV-to-EBITDA 31.35
HSKA's EV-to-EBITDA is ranked lower than
72% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.53 vs. HSKA: 31.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSKA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43  Med: 12.9 Max: 59.1
Current: 31.35
-43
59.1
PEG Ratio 1.57
HSKA's PEG Ratio is ranked higher than
82% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. HSKA: 1.57 )
Ranked among companies with meaningful PEG Ratio only.
HSKA' s PEG Ratio Range Over the Past 10 Years
Min: 1.57  Med: 51.7 Max: 65.79
Current: 1.57
1.57
65.79
Shiller PE Ratio 88.42
HSKA's Shiller PE Ratio is ranked lower than
84% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.11 vs. HSKA: 88.42 )
Ranked among companies with meaningful Shiller PE Ratio only.
HSKA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 7.39  Med: 23.29 Max: 254.5
Current: 88.42
7.39
254.5
Current Ratio 1.83
HSKA's Current Ratio is ranked lower than
64% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.72 vs. HSKA: 1.83 )
Ranked among companies with meaningful Current Ratio only.
HSKA' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.92 Max: 5.19
Current: 1.83
1.03
5.19
Quick Ratio 1.00
HSKA's Quick Ratio is ranked lower than
82% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. HSKA: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
HSKA' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 1.08 Max: 4.4
Current: 1
0.56
4.4
Days Inventory 95.67
HSKA's Days Inventory is ranked lower than
56% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. HSKA: 95.67 )
Ranked among companies with meaningful Days Inventory only.
HSKA' s Days Inventory Range Over the Past 10 Years
Min: 82.09  Med: 106.38 Max: 109.49
Current: 95.67
82.09
109.49
Days Sales Outstanding 38.87
HSKA's Days Sales Outstanding is ranked higher than
79% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.14 vs. HSKA: 38.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSKA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.87  Med: 49.25 Max: 58.52
Current: 38.87
38.87
58.52
Days Payable 26.64
HSKA's Days Payable is ranked lower than
83% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.94 vs. HSKA: 26.64 )
Ranked among companies with meaningful Days Payable only.
HSKA' s Days Payable Range Over the Past 10 Years
Min: 26.64  Med: 34.99 Max: 46.37
Current: 26.64
26.64
46.37

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.90
HSKA's 5-Year Yield-on-Cost % is ranked lower than
67% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.25 vs. HSKA: 0.90 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
HSKA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.79  Med: 2.22 Max: 3.73
Current: 0.9
0.79
3.73
3-Year Average Share Buyback Ratio -6.30
HSKA's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. HSKA: -6.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HSKA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.6  Med: -2.75 Max: -0.4
Current: -6.3
-38.6
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 49.55
HSKA's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.67 vs. HSKA: 49.55 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HSKA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.37  Med: 3.9 Max: 207.5
Current: 49.55
2.37
207.5
Price-to-Tangible-Book 10.90
HSKA's Price-to-Tangible-Book is ranked lower than
75% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.04 vs. HSKA: 10.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HSKA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.3  Med: 2.34 Max: 261.43
Current: 10.9
0.3
261.43
Price-to-Intrinsic-Value-Projected-FCF 9.22
HSKA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
90% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. HSKA: 9.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HSKA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.05 Max: 20.8
Current: 9.22
0.57
20.8
Price-to-Median-PS-Value 7.08
HSKA's Price-to-Median-PS-Value is ranked lower than
100% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. HSKA: 7.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HSKA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.11 Max: 16.76
Current: 7.08
0.21
16.76
Price-to-Graham-Number 5.05
HSKA's Price-to-Graham-Number is ranked lower than
64% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. HSKA: 5.05 )
Ranked among companies with meaningful Price-to-Graham-Number only.
HSKA' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.2  Med: 2.61 Max: 44
Current: 5.05
0.2
44
Earnings Yield (Greenblatt) % 2.55
HSKA's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. HSKA: 2.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HSKA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8.7  Med: 3.5 Max: 21.2
Current: 2.55
-8.7
21.2
Forward Rate of Return (Yacktman) % -2.88
HSKA's Forward Rate of Return (Yacktman) % is ranked lower than
80% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. HSKA: -2.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HSKA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.3  Med: -2 Max: 7.5
Current: -2.88
-15.3
7.5

More Statistics

Revenue (TTM) (Mil) $133.32
EPS (TTM) $ 1.87
Beta0.52
Short Percentage of Float3.69%
52-Week Range $32.27 - 110.25
Shares Outstanding (Mil)7.12

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 143 161 176
EPS ($) 1.88 2.15 2.40
EPS without NRI ($) 1.88 2.15 2.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
16.80%
Dividends per Share ($)
» More Articles for HSKA

Headlines

Articles On GuruFocus.com
Scott Humphrey Joins Heska's Board of Directors Jun 13 2017 
Heska Reports First Quarter Results May 02 2017 
Heska To Present at Four Upcoming Conferences Apr 27 2017 
Reminder: Heska Annual Meeting of Stockholders on May 1, 2017 Apr 25 2017 
Heska Schedules First Quarter 2017 Financial Results Conference Call for May 2, 2017 Apr 13 2017 
Heska Schedules Annual Meeting of Stockholders for May 1, 2017 Apr 12 2017 
Gartner Set to Join S&P 500; Dun & Bradstreet, Wintrust Financial and INC Research to Join S&P MidCa Mar 31 2017 
'Kittens Equal Happiness': GAMCO Analyst on Zoetis, Heska, Smuckers Oct 07 2016 
Heska's Still has Room to Run Aug 19 2016 
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 

More From Other Websites
Heska Corp. breached its 50 day moving average in a Bullish Manner : HSKA-US : June 22, 2017 Jun 22 2017
ETFs with exposure to Heska Corp. : June 19, 2017 Jun 19 2017
Heska Corp. :HSKA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Scott Humphrey Joins Heska's Board of Directors Jun 13 2017
Edited Transcript of HSKA earnings conference call or presentation 2-May-17 3:00pm GMT Jun 08 2017
Why Heska (HSKA) Could Be Positioned for a Surge Jun 02 2017
Heska Corp. breached its 50 day moving average in a Bearish Manner : HSKA-US : May 26, 2017 May 26 2017
Heska Corp. – Value Analysis (NASDAQ:HSKA) : May 4, 2017 May 04 2017
Here's Why Heska Corporation Is Dropping Today May 02 2017
Heska posts 1Q profit May 02 2017
Investor Network: Heska Corporation to Host Earnings Call May 02 2017
Heska Reports First Quarter Results May 02 2017
Hill-Rom (HRC) Beats Earnings & Revenue Estimates in Q2 May 01 2017
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up Apr 28 2017
Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates Apr 28 2017
Align Technology (ALGN) Beats on Q1 Earnings and Revenues Apr 28 2017
Chemed's (CHE) Earnings and Revenues Beat Estimates in Q1 Apr 27 2017
Heska To Present at Four Upcoming Conferences Apr 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}